期刊
BIOCHEMICAL PHARMACOLOGY
卷 79, 期 11, 页码 1544-1552出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2010.01.015
关键词
Cancer; Tumor necrosis factor (TNF); Hodgkin's lymphoma (HL); Anaplastic large cell lymphomas (ALCL); Hematologic malignancies; Lymphoproliferative diseases; Reed-Sternberg cells; Antibody-drug conjugates; Immunotoxins; Immune evasion
The immunotherapy of Hodgkin's lymphoma (HL) has been particularly challenging because of the unique features of tumor intrinsic and host mediated factors, interfering with the antitumor activities of therapeutic antibodies. Despite a wide array of compounds tested successfully in preclinical studies, immunotherapy in HL patients resulted in only limited success when compared to the significant improvements in patient survival provided by chemotherapeutic agents. Antibody drug conjugates (ADCs) may surmount the restrictions posed by the unique pathobiology of HL tumors as they combine the selective tumor targeting of monoclonal antibodies with the potent anti-neoplastic activities of cytotoxic drugs. In early clinical trials, this class of compounds induced robust antitumor effects in patients with relapsed or refractory lymphoproliferative diseases, in the absence of overt toxicities, while naked antibodies failed to induce therapeutic benefit. Here we review some of the unique features of HL tumor biology and the key advantages of ADC-based lymphoma therapies, which may ultimately account for the improved therapeutic benefit provided by ADCs compared to first generation immunotherapeutics tested in HL patients. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据